New hope for tough prostate cancer: RS-113 drug trial underway
NCT ID NCT07553988
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This study tests a new drug called RS-113 in 120 men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the best dose that can slow or stop cancer growth, comparing it to an existing drug, abiraterone. Participants will receive RS-113 and be monitored for side effects and how long their cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City Clinical Oncology Dispensary (Saint Petersburg)
Saint Petersburg, 198255, Russia
-
Federal State Autonomous Institution "National Medical Research Center 'Medical and Rehabilitation Center'" of the Ministry of Health of the Russian Federation
Moscow, 125367, Russia
-
Ivanovo Regional Oncology Dispensary
Ivanovo, 153040, Russia
-
Joint-Stock Company "Medsi Group of Companies"
Moscow, 143442, Russia
-
Kaluga Regional Clinical Oncology Dispensary
Kaluga, 248007, Russia
-
LLC MSCh "Klinitsist-Klinika Pretor"
Novosibirsk, 630091, Russia
-
Moscow City Clinical Oncology Hospital No. 62 of the Moscow Department of Healthcare
Istra, 143515, Russia
-
Multidisciplinary Clinical Medical Center "Medical City"
Tyumen, 625041, Russia
-
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Moscow, 125284, Russia
-
Oncology Center No. 1 of the City Clinical Hospital named after S.S. Yudin of the Moscow Healthcare Department
Moscow, 117152, Russia
-
Private Healthcare Institution "Clinical Hospital "RZD-Medicine" of Saint-Petersburg"
Saint Petersburg, 195271, Russia
-
Research Lab LLC
Moscow, 127521, Russia
-
Siberian State Medical University
Tomsk, 634063, Russia
-
State Budgetary Healthcare Institution "Leningrad Regional Clinical Hospital"
Kuz'molovskiy, 191104, Russia
-
State Budgetary Healthcare Institution of the Arkhangelsk Region "Arkhangelsk Oncology Dispensary"
Arkhangelsk, 163045, Russia
-
State Institution of Healthcare of Yaroslavl Region "Regional Oncology Hospital"
Yaroslavl, 150054, Russia
Conditions
Explore the condition pages connected to this study.